MDRX, US01988P1084

Veradigm discloses patient-data breach: USD 8 target for Veradigm stock

Published on 10/16/2026 at 04:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veradigm expected 2025 revenue of USD 584 million to USD 589 million at its September 2026 update. A USD 8.00 target was cited for Veradigm stock.

Cybersecurity and valuation context

A September 8, 2026 Form 8-K covered a vendor-related patient-data incident.
Expected 2025 revenue stood at USD 584 million to USD 589 million.
A USD 8.00 target was the latest analyst valuation cited on September 16, 2026.

MDRX, US01988P1084, Illustration mit AI erstellt.

Veradigm (ISIN US01988P1084) disclosed in a September 8, 2026 Form 8-K that credentials taken from a third-party vendor were used to download patient data, including Social Security numbers, through a limited application programming interface, according to Top Class Actions. The incident gives investors a concrete test of Veradigm's operating controls as the company works toward a broader market relisting.

What does the breach change?

The reported access was limited to one vendor-connected interface. The report said no clinical or medical data was involved, the credentials did not open Veradigm's wider network, and the incident caused no operational disruption. Veradigm activated response procedures, notified law enforcement, and began contacting affected customers and individuals.

The report also said the company had not quantified potential liabilities and did not expect a material impact on its business or financial condition based on the information available at that time. That combination puts the emphasis on follow-up disclosures, customer communication, and the cost of remediation rather than on a reported interruption to daily operations.

Revenue and balance sheet figures

At investor conferences on September 15 and September 16, 2026, Veradigm presented a transformation plan built around simplifying products, improving customer experience, and unifying operations across providers, payers, and life sciences, according to The Globe and Mail. The same update put expected 2025 revenue at USD 584 million to USD 589 million, with USD 120 million in cash and USD 75 million in debt at year-end 2025.

The figures imply USD 45 million more cash than debt at that historical year-end reference. The update also described completed 2023 and 2024 annual filings, an ongoing 2025 audit, and a plan to become current in SEC reporting before seeking relisting on a national exchange.

Valuation depends on execution

The latest analyst valuation cited by The Globe and Mail on September 16, 2026 was a Buy rating with a USD 8.00 target. That target sits alongside a transformation story that still depends on filing progress, customer retention, and the handling of the vendor incident.